

GRANTED FDA BREAKTHROUGH STATUS.

Approved for adults with HER2-low metastatic breast cancer (mBC) who have received chemotherapy for mBC or who have breast cancer that has come back within 6 months of completing chemotherapy after surgery

With ENHERTU,
**I STAND
ENCOURAGED**

Not an actual patient.

UNDERSTANDING AND MANAGING POTENTIAL SIDE EFFECTS OF ENHERTU

HER2, human epidermal growth factor receptor 2.

What is ENHERTU?

ENHERTU is a prescription medicine used to treat adults who have:

- HER2-low breast cancer that cannot be removed by surgery or that has spread to other parts of your body (metastatic), and who have received a prior chemotherapy:
 - for metastatic disease, **or**
 - your disease has returned during or within 6 months of completing adjuvant chemotherapy (after surgery). Your healthcare provider will perform a test to make sure ENHERTU is right for you

It is not known if ENHERTU is safe and effective in children.

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about ENHERTU?

ENHERTU can cause serious side effects, including:

Lung problems that may be severe, life-threatening or that may lead to death.

If you develop lung problems your healthcare provider may treat you with corticosteroid medicines. Tell your healthcare provider right away if you get any of the following signs and symptoms:

- Cough
- Trouble breathing or shortness of breath
- Fever
- Other new or worsening breathing symptoms (e.g., chest tightness, wheezing)

Please see additional Important Safety Information on pages 12-15 of this brochure, and [click here for full ENHERTU Prescribing Information](#), including Boxed WARNINGS, and [click here for Medication Guide](#).

 **ENHERTU**[®]
fam-trastuzumab deruxtecan-nxki
20 mg/mL INJECTION FOR INTRAVENOUS USE

Is ENHERTU right for me?

During treatment with ENHERTU, it's possible to experience side effects, so it's important that you know what to look out for. This guide will help you understand and manage these side effects with your healthcare team.

Remember to always keep your healthcare team informed about how you're feeling

ENHERTU is a prescription medicine used to treat adults who have:

- HER2-low breast cancer that cannot be removed by surgery or that has spread to other parts of your body (metastatic), and who have received a prior chemotherapy:
 - for metastatic disease, **or**
 - your disease has returned during or within 6 months of completing adjuvant chemotherapy (after surgery). Your healthcare provider will perform a test to make sure ENHERTU is right for you

It is not known if ENHERTU is safe and effective in children.

ENHERTU was studied in many types of adults, including those with different:

- Ages
- HR status
- Levels of HER2
- Number of previous treatments

Find more information at [ENHERTU.com/discover](https://www.enhertu.com/discover)

HER2, human epidermal growth factor receptor 2; HR, hormone receptor.

Important Safety Information (cont'd)

Low white blood cell counts (neutropenia). Low white blood cell counts are common with ENHERTU and can sometimes be severe. Your healthcare provider will check your white blood cell counts before starting ENHERTU and before starting each dose. Tell your healthcare provider right away if you develop any signs or symptoms of an infection or have fever or chills during treatment with ENHERTU.

Please see additional Important Safety Information on pages 12-15 of this brochure, and [click here for full ENHERTU Prescribing Information](#), including Boxed WARNINGS, and [click here for Medication Guide](#).

 **ENHERTU[®]**
fam-trastuzumab deruxtecan-nxki
20 mg/mL INJECTION FOR INTRAVENOUS USE



Not an actual patient.

Important Safety Information (cont'd)

Heart problems that may affect your heart's ability to pump blood.

Your healthcare provider will check your heart function before starting treatment with ENHERTU. Tell your healthcare provider right away if you get any of the following signs and symptoms:

- New or worsening shortness of breath
- Coughing
- Feeling tired
- Swelling of your ankles or legs
- Irregular heartbeat
- Sudden weight gain
- Dizziness or feeling light-headed
- Loss of consciousness

Please see additional Important Safety Information on pages 12-15 of this brochure, and [click here for full ENHERTU Prescribing Information](#), including Boxed WARNINGS, and [click here for Medication Guide](#).

 **ENHERTU[®]**
fam-trastuzumab deruxtecan-nxki
20 mg/mL INJECTION FOR INTRAVENOUS USE

ENHERTU is taken alone, without the need for other medicines, to treat metastatic breast cancer

ENHERTU is given as an intravenous (IV) infusion. This means it is given through a needle or tube into your vein. You will receive an ENHERTU infusion once every 3 weeks, most likely at your oncologist's office or at a nearby infusion center.



The first infusion will take about 90 minutes so the healthcare provider can see if there are any side effects or problems

Future infusions should take about 30 minutes, if your first infusion was well tolerated

If you miss a planned dose of ENHERTU, call your healthcare provider right away to schedule an appointment. Do not wait until the next planned treatment cycle.

Important Safety Information (cont'd)

Your healthcare provider will check you for these side effects during your treatment with ENHERTU. Your healthcare provider may reduce your dose, delay treatment or completely stop treatment with ENHERTU if you have severe side effects.

Please see additional Important Safety Information on pages 12-15 of this brochure, and [click here for full ENHERTU Prescribing Information](#), including Boxed WARNINGS, and [click here for Medication Guide](#).

 **ENHERTU[®]**
fam-trastuzumab deruxtecan-nxki
20 mg/mL INJECTION FOR INTRAVENOUS USE

To help manage your side effects, your healthcare provider may:



Reduce your dose



Delay your dose

Stop ENHERTU

Your healthcare provider will give you medicines before your infusion to help prevent nausea and vomiting.

Important Safety Information (cont'd)

Harm to your unborn baby. Tell your healthcare provider right away if you become pregnant or think you might be pregnant during treatment with ENHERTU.

- If you are able to become pregnant, your healthcare provider should do a pregnancy test before you start treatment with ENHERTU.
- **Females** who are able to become pregnant should use effective birth control (contraception) during treatment with ENHERTU and for 7 months after the last dose.
- **Males** who have female partners that are able to become pregnant should use effective birth control (contraception) during treatment with ENHERTU and for 4 months after the last dose.

Before you receive ENHERTU, tell your healthcare provider about all of your medical conditions, including if you:

- Have lung or breathing problems.
- Have kidney problems. Your healthcare provider may follow you more closely. In clinical trials, more serious lung problems were seen in patients with certain kidney problems.
- Have liver problems. Your healthcare provider may follow you more closely.
- Have signs or symptoms of an infection.
- Have or have had any heart problems.
- Are breastfeeding or plan to breastfeed. It is not known if ENHERTU passes into your breast milk. Do not breastfeed during treatment with ENHERTU and for 7 months after the last dose.

Please see additional Important Safety Information on pages 12-15 of this brochure, and [click here for full ENHERTU Prescribing Information](#), including Boxed WARNINGS, and [click here for Medication Guide](#).

 **ENHERTU[®]**
fam-trastuzumab deruxtecan-nxki
20 mg/mL INJECTION FOR INTRAVENOUS USE

What are the most common side effects of ENHERTU?

The most common side effects of ENHERTU when used at the 5.4 mg/kg dose include:

- Nausea
- Low white blood cell counts
- Low red blood cell counts
- Feeling tired
- Low platelet counts
- Increased liver function tests
- Vomiting
- Hair loss
- Constipation
- Muscle or bone pain
- Decreased appetite
- Low levels of blood potassium
- Diarrhea
- Cough

ENHERTU may cause fertility problems in males, which may affect the ability to father children. Talk to your healthcare provider if you have concerns about fertility.

These are not all the possible side effects of ENHERTU. Call your healthcare provider for medical advice about side effects. You are encouraged to report negative side effects of ENHERTU by calling 1-877-437-7763. If you prefer to report these to the FDA, visit www.FDA.gov/medwatch or call 1-800-FDA-1088 (1-800-332-1088)

Please see additional Important Safety Information on pages 12-15 of this brochure, and [click here for full ENHERTU Prescribing Information](#), including Boxed WARNINGS, and [click here for Medication Guide](#).

 **ENHERTU[®]**
fam-trastuzumab deruxtecan-nxki
20 mg/mL INJECTION FOR INTRAVENOUS USE

Tips for managing common side effects

Consider using the tips below to help manage some of the common side effects that may happen during treatment

These tips are not intended to take the place of your healthcare team's advice. Always talk to your healthcare provider first.

For nausea and vomiting

- Try to eat 5 or 6 small meals and snacks each day instead of 3 large meals
- Eat bland, easy-to-digest food and drinks
- Avoid food and drinks that are too hot or too cold
- Avoid strong smells, if possible
- If you are vomiting, take deep, slow breaths and, if possible, get fresh air

For diarrhea

- Try to eat 5 or 6 small meals and snacks each day instead of 3 large meals
- Eat foods low in fiber
- Drink clear liquids to replace lost fluids. Check with your healthcare provider to figure out how much and what types of fluid might be best



For tiredness or fatigue

- Try activities such as meditation, which helps with relaxation and decreases stress
- Plan rest time and try not to do too much
- Try regular exercise during times when your energy level is high (according to your healthcare provider's approval)
- Let other people help you with everyday tasks

Please see additional Important Safety Information on pages 12-15 of this brochure, and [click here for full ENHERTU Prescribing Information](#), including Boxed WARNINGS, and [click here for Medication Guide](#).

 **ENHERTU[®]**
fam-trastuzumab deruxtecan-nxki
20 mg/mL INJECTION FOR INTRAVENOUS USE

Tips for managing common side effects (cont'd)



For dealing with hair thinning or hair loss (alopecia)

Before hair thinning or hair loss:

- Talk to your healthcare provider about the possibility of hair thinning or hair loss
- Consider cutting your hair short to feel more in control of hair loss
- Be gentle when you wash your hair. Use a mild shampoo, such as baby shampoo
- Avoid items such as electric hair dryers, hairspray, hair dyes, products to perm or relax hair, hair bands, and/or clips that can hurt your scalp
- Consider asking your healthcare provider about cold caps or scalp cooling systems. These may help reduce hair loss by narrowing the blood vessels beneath your scalp
- If you plan on buying a wig, do so while you still have hair

If hair thinning or hair loss occurs:

- Protect your scalp by wearing a hat or head covering, applying sunscreen, and avoiding very hot or sunny places when possible
- Cover your head to help stay warm as well—you may feel colder if you lose your hair
- Sleep on a satin pillowcase. Satin creates less friction and may be more comfortable

Please see additional Important Safety Information on pages 12-15 of this brochure, and [click here for full ENHERTU Prescribing Information](#), including Boxed WARNINGS, and [click here for Medication Guide](#).

 **ENHERTU[®]**
fam-trastuzumab deruxtecan-nxki
20 mg/mL INJECTION FOR INTRAVENOUS USE

What is the most important information you should know about ENHERTU?

ENHERTU can cause side effects. Some serious or life-threatening side effects may affect your lungs, heart, or white blood cell count, affecting your ability to fight infection

Pay special attention to new or worsening symptoms as they may be related to:

Lung problems, like interstitial lung disease/ pneumonitis, that may be severe, life-threatening or that may lead to death

Call or see your healthcare provider right away if you develop any of the following signs and symptoms or if these symptoms get worse:

- Cough
- Trouble breathing or shortness of breath
- Fever
- Other new or worsening breathing symptoms (e.g., chest tightness, wheezing)

If lung problems develop, your healthcare provider may treat you with corticosteroid medicines.

Getting medical treatment right away may help keep these problems from becoming more serious

Please see additional Important Safety Information on pages 12-15 of this brochure, and [click here for full ENHERTU Prescribing Information](#), including Boxed WARNINGS, and [click here for Medication Guide](#).

 **ENHERTU[®]**
fam-trastuzumab deruxtecan-nxki
20 mg/mL INJECTION FOR INTRAVENOUS USE

What is the most important information you should know about ENHERTU? (cont'd)

Low white blood cell count (neutropenia)

- Low white blood cell counts are common with ENHERTU and can sometimes be severe
- Your healthcare provider will check your white blood cell counts before starting ENHERTU and before starting each dose
- Tell your healthcare provider right away if you develop any signs or symptoms of an infection or have fever or chills during treatment with ENHERTU

Heart problems that may affect your heart's ability to pump blood

Your healthcare provider will check your heart function before starting treatment with ENHERTU.

Signs and symptoms may include:

- New or worsening shortness of breath
- Coughing
- Feeling tired
- Swelling of your ankles or legs
- Irregular heartbeat
- Sudden weight gain
- Dizziness or feeling light-headed
- Loss of consciousness

Your healthcare provider will check you for these side effects during your treatment with ENHERTU.

Your healthcare provider may reduce your dose, delay treatment, or completely stop treatment with ENHERTU if you have severe side effects

Please see additional Important Safety Information on pages 12-15 of this brochure, and [click here for full ENHERTU Prescribing Information](#), including Boxed WARNINGS, and [click here for Medication Guide](#).

 **ENHERTU[®]**
fam-trastuzumab deruxtecan-nxki
20 mg/mL INJECTION FOR INTRAVENOUS USE



Not an actual patient.

Harm to your unborn baby

Tell your healthcare provider right away if you become pregnant or think you might be pregnant during treatment with ENHERTU.

- If you are able to become pregnant, your healthcare provider should do a pregnancy test before you start treatment with ENHERTU.
- **Females** who are able to become pregnant should use effective birth control (contraception) during treatment with ENHERTU and for 7 months after the last dose.
- **Males** who have female partners that are able to become pregnant should use effective birth control (contraception) during treatment with ENHERTU and for 4 months after the last dose.

Please see additional Important Safety Information on pages 12-15 of this brochure, and [click here for full ENHERTU Prescribing Information](#), including Boxed WARNINGS, and [click here for Medication Guide](#).

 **ENHERTU[®]**
fam-trastuzumab deruxtecan-nxki
20 mg/mL INJECTION FOR INTRAVENOUS USE

Important Safety Information

What is the most important information I should know about ENHERTU?

ENHERTU can cause serious side effects, including:

Lung problems that may be severe, life-threatening or that may lead to death. If you develop lung problems your healthcare provider may treat you with corticosteroid medicines. Tell your healthcare provider right away if you get any of the following signs and symptoms:

- Cough
- Trouble breathing or shortness of breath
- Fever
- Other new or worsening breathing symptoms (e.g., chest tightness, wheezing)

Low white blood cell counts (neutropenia). Low white blood cell counts are common with ENHERTU and can sometimes be severe. Your healthcare provider will check your white blood cell counts before starting ENHERTU and before starting each dose. Tell your healthcare provider right away if you develop any signs or symptoms of an infection or have fever or chills during treatment with ENHERTU.

Heart problems that may affect your heart's ability to pump blood.

Your healthcare provider will check your heart function before starting treatment with ENHERTU. Tell your healthcare provider right away if you get any of the following signs and symptoms:

- New or worsening shortness of breath
- Coughing
- Feeling tired
- Swelling of your ankles or legs
- Irregular heartbeat
- Sudden weight gain
- Dizziness or feeling light-headed
- Loss of consciousness

Please see additional Important Safety Information on pages 12-15 of this brochure, and [click here for full ENHERTU Prescribing Information](#), including Boxed WARNINGS, and [click here for Medication Guide](#).

 **ENHERTU[®]**
fam-trastuzumab deruxtecan-nxki
20 mg/mL INJECTION FOR INTRAVENOUS USE

Your healthcare provider will check you for these side effects during your treatment with ENHERTU. Your healthcare provider may reduce your dose, delay treatment or completely stop treatment with ENHERTU if you have severe side effects.

Harm to your unborn baby. Tell your healthcare provider right away if you become pregnant or think you might be pregnant during treatment with ENHERTU.

- If you are able to become pregnant, your healthcare provider should do a pregnancy test before you start treatment with ENHERTU.
- **Females** who are able to become pregnant should use effective birth control (contraception) during treatment with ENHERTU and for 7 months after the last dose.
- **Males** who have female partners that are able to become pregnant should use effective birth control (contraception) during treatment with ENHERTU and for 4 months after the last dose.

Before you receive ENHERTU, tell your healthcare provider about all of your medical conditions, including if you:

- Have lung or breathing problems.
- Have signs or symptoms of an infection.
- Have or have had any heart problems.
- Are breastfeeding or plan to breastfeed. It is not known if ENHERTU passes into your breast milk. Do not breastfeed during treatment with ENHERTU and for 7 months after the last dose.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Please see additional Important Safety Information on pages 12-15 of this brochure, and [click here for full ENHERTU Prescribing Information](#), including Boxed WARNINGS, and [click here for Medication Guide](#).

 **ENHERTU[®]**
fam-trastuzumab deruxtecan-nxki
20 mg/mL INJECTION FOR INTRAVENOUS USE

Important Safety Information (cont'd)

How will I receive ENHERTU?

- You will receive ENHERTU into your vein through an intravenous (IV) line by your healthcare provider.
- ENHERTU is given 1 time every three weeks (21-day treatment cycle).
- Your healthcare provider will decide how many treatments you need.
- Your healthcare provider will give you medicines before your infusion to help prevent nausea and vomiting.
- Your healthcare provider may slow down or temporarily stop your infusion of ENHERTU if you have an infusion-related reaction, or permanently stop ENHERTU if you have severe infusion reactions.
- If you miss a planned dose of ENHERTU, call your healthcare provider right away to schedule an appointment. Do not wait until the next planned treatment cycle.

What are the possible side effects of ENHERTU?

ENHERTU can cause serious side effects. See “What is the most important information I should know about ENHERTU?”

The most common side effects of ENHERTU when used at the 5.4 mg/kg dose include:

- | | |
|----------------------------------|---------------------------------|
| • Nausea | • Hair loss |
| • Low white blood cell counts | • Constipation |
| • Low red blood cell counts | • Muscle or bone pain |
| • Feeling tired | • Decreased appetite |
| • Low platelet counts | • Low levels of blood potassium |
| • Increased liver function tests | • Diarrhea |
| • Vomiting | • Cough |

ENHERTU may cause fertility problems in males, which may affect the ability to father children. Talk to your healthcare provider if you have concerns about fertility.

These are not all of the possible side effects of ENHERTU. Call your doctor for medical advice about side effects. You may report side effects to Daiichi Sankyo at 1-877-437-7763 or to FDA at 1-800-FDA-1088.

Please see additional Important Safety Information on pages 12-15 of this brochure, and [click here for full ENHERTU Prescribing Information](#), including Boxed WARNINGS, and [click here for Medication Guide](#).

 **ENHERTU®**
fam-trastuzumab deruxtecan-nxki
20 mg/mL INJECTION FOR INTRAVENOUS USE

What is ENHERTU?

ENHERTU is a prescription medicine used to treat adults who have:

- HER2-low breast cancer that cannot be removed by surgery or that has spread to other parts of your body (metastatic), and who have received a prior chemotherapy:
 - for metastatic disease, **or**
 - your disease has returned during or within 6 months of completing adjuvant chemotherapy (after surgery). Your healthcare provider will perform a test to make sure ENHERTU is right for you

It is not known if ENHERTU is safe and effective in children.

Please see full Prescribing Information, including Boxed WARNINGS, and Medication Guide.

Not actual patients.



Please see additional Important Safety Information on pages 12-15 of this brochure, and [click here for full ENHERTU Prescribing Information](#), including Boxed WARNINGS, and [click here for Medication Guide](#).

 **ENHERTU[®]**
fam-trastuzumab deruxtecan-nxki
20 mg/mL INJECTION FOR INTRAVENOUS USE



Find out more about ENHERTU

Talk to your healthcare provider
and visit [ENHERTU.com/discover](https://www.enherthu.com/discover)
or scan the QR code



Not an actual patient.

References: **1.** FDA Approves First Targeted Therapy for HER2-Low Breast Cancer. FDA news release. U.S. Food & Drug Administration. August 5, 2022. Accessed August 5, 2022. <https://www.fda.gov/news-events/press-announcements/fda-approves-first-targeted-therapy-her2-low-breast-cancer>. **2.** ENHERTU [prescribing information]. Daiichi Sankyo Inc., Basking Ridge, NJ and AstraZeneca Pharmaceuticals LP, Wilmington, DE, 2022. **3.** Support for People with Cancer: Chemotherapy and You. National Cancer Institute. Accessed December 20, 2021. <https://www.cancer.gov/publications/patient-education/chemotherapy-and-you.pdf>. **4.** BreastCancer.org. Cold caps and scalp cooling systems. Accessed June 16, 2022. <https://www.breastcancer.org/treatment/side-effects/hair-loss/cold-caps-scalp-cooling>.

Please see additional Important Safety Information on pages 12-15 of this brochure, and [click here for full ENHERTU Prescribing Information](#), including Boxed WARNINGS, and [click here for Medication Guide](#).

 **ENHERTU**[®]
fam-trastuzumab deruxtecan-nxki
20 mg/mL INJECTION FOR INTRAVENOUS USE

 Daiichi-Sankyo

AstraZeneca 

ENHERTU[®] is a registered trademark of Daiichi Sankyo Company, Limited.
© 2022 Daiichi Sankyo, Inc. and AstraZeneca. PP-US-ENB-1450 09/22